A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ORAL ALPHA-4 INTEGRIN INHIBITOR (AJM300) IN PATIENTS WITH ACTIVE CROHN’S DISEASE

(1) Internal medicine, Social Insurance Central General Hospita

(2) Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo

(3) Division of Lower Gastroenterology Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya

(4) Gastroenterology, Izumiohtu City Hospital, Izumiohtu

(5) Internal medicine, Iwaki Kyoritsu General Hospital, Iwaki

(6) Internal medicine, Keio University School of Medicine, Tokyo, Japan



This item was part of the New approaches to IBD therapy: Stem cells and other agents session at Gastro 2009 UEGW/WCOG London (17th UEGW)

This item can be cited as: Gut 2009; 58 (Suppl II) A11